AliveCor Launches KardiaComplete to Help Reduce the Rising Health and Economic Costs of Heart Disease

AliveCor today announced the launch of KardiaComplete, a comprehensive heart health enterprise solution designed to drive improved health outcomes and reduce the cost of cardiac care.

The service will be available to people diagnosed with hypertension and arrhythmias, like atrial fibrillation, through their self-insured employers, health insurance plans and health systems.

KardiaComplete also addresses the urgent need to democratize heart care as the United States faces a significant cardiologist shortage.1 By leveraging data from best-in-class cardiac monitoring solutions – AliveCor’s KardiaMobile 6L, the #1 doctor-recommended personal ECG, and Omron’s Evolv, the #1 doctor and pharmacist-recommended blood pressure cuff – KardiaComplete meets people’s need for coaching and care in the moments that matter.

“KardiaComplete goes beyond short-term monitoring and education to offer payers and employers a more robust solution to manage patient care and drive lasting results,” said Priya Abani, Chief Executive Officer, AliveCor. “We have brought our deep heritage in AI and user-friendly devices and services to invent a single virtual disease management program that can augment existing programs and streamline patient care.”

Fueled by AliveCor’s AI-powered connected devices and services, KardiaComplete’s specialized live and digital heart health coaching helps address these conditions by offering lifestyle management tools that promote heart-healthy diet, movement, stress management and healthy sleep. In addition, a nationwide affiliated cardiologist care team co-manages patients with their primary care physicians utilizing evidence-based medication recommendations to help improve clinical outcomes.

KardiaComplete also offers support from a virtual assistant and personalized analyses of heart data to empower people living with heart conditions to better manage their health. Together, these features are designed to improve patient outcomes and reduce spending. In a modeled claims analysis of eligible commercial health plan members with hypertension and/or atrial fibrillation, KardiaComplete saved an estimated $160 per enrollee per month after one year by saving on acute events and disease progression.2

“Reducing the cost of heart care requires not only addressing established disease but also reducing the risk of disease progression that can lead to even greater downstream economic impacts,” said Archana Dubey, MD, Chief Clinical Officer, AliveCor. “By making it easier for people to take positive steps earlier in their journey, KardiaComplete aims to help those with early disease prevent further disease progression, and those with established disease to contain cardiovascular damage that can lead to stroke, congestive heart failure and other serious conditions.”

AliveCor plans to expand its future KardiaComplete offerings to people living with other serious heart conditions, such as heart failure and coronary artery disease.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.